Sanofi Lawsuit Delays OTC Nasacort Generic Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.
You may also be interested in...
Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost
French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.
Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost
French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.
Sanofi Sues FDA To Stop Publication Of Nasacort Labeling Before Launch
After FDA denied Sanofi three years of market exclusivity for OTC Nasacort, the firm filed suit against the agency not to publish the product’s labeling prior to the launch. If successful, the firm could postpone the launch of generic competition.